NASDAQ$GDRX
GoodRx Holdings Inc. · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
GoodRx's first quarter financial results exceeded previously announced guidance.
GoodRx's total revenue decreased by 10% to $184.0 million compared to $203.3 million. Net loss was $3.3 million compared to a net income of $12.3 million. Adjusted EBITDA was $53.2 million compared to $64.7 million.
- Total revenue of $184.0 million, exceeding previously announced guidance
- Net loss of $3.3 million; Net loss margin of 1.8%
- Adjusted EBITDA of $53.2 million; Adjusted EBITDA Margin of 28.9%, exceeding previously announced guidance
- Over 450,000 prescribers engaged with us through Provider Mode since its launch
Headline financials
Revenue & EPS history
GoodRx · Revenue · Quarterly
$184M
Revenue by segment
GoodRx · $179M total across 3 segments · Q1 2023
- Prescription Transactions$135M—75.2%
- Subscription$24.1M—13.4%
- Pharma Direct$20.4M—11.4%
Forward guidance
For the second quarter and full year 2023, management is anticipating total revenue of ~$185-188 million and ~$750-775 million respectively. Adjusted EBITDA Margin is expected to be in the mid-twenty-percent range.
Tailwinds
- Ongoing focus on driving efficiency throughout our organization
- Strengthening our ecosystem and consumer engagement
- Solid revenue and Adjusted EBITDA Margin improvement
- Strong balance sheet and liquidity position
- Generating robust operating cash flow
Headwinds
- Total Revenue 2Q 2023 ~$185-188 million vs 2Q 2022 $191.8 million
- Total Revenue FY 2023 ~$750-775 million vs FY 2022 $766.6 million
- The grocer issue
- Impact of macroeconomic conditions
- Uncertainty and potential variability of stock-based compensation expense
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
-5.3%
Avg return
Earnings day
-8.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
37%
10 / 27 earnings
Positive
+29.1%
Q4 2023
Best reaction
-37.4%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | +10.5% | +3.5% | |
| Q4 2025 | -19.5% | -15.5% | -20.8% | |
| Q3 2025 | +1.8% | -6.1% | -16.9% | |
| Q1 2025 | +11.9% | +13.5% | +7.7% | |
| Q4 2024 | +1.8% | -4.5% | -8.0% | |
| Q3 2024 | -20.0% | -23.1% | -19.6% | |
| Q2 2024 | -16.3% | -20.2% | -10.5% | |
| Q1 2024 | -13.3% | -12.6% | +12.4% | |
| Q4 2023 | +29.1% | +17.6% | +9.7% | |
| Q3 2023 | -12.4% | -8.8% | +9.1% | |
| Q2 2023 | -5.6% | -14.1% | -29.3% | |
| Q1 2023 | +7.0% | +10.9% | +17.5% | |
| Q4 2022 | +5.6% | +13.6% | +14.2% | |
| Q3 2022 | -21.5% | +10.4% | +0.8% | |
| Q2 2022 | +10.5% | +4.1% | -12.6% | |
| Q1 2022 | -37.4% | -30.1% | -43.5% | |
| Q4 2021 | -36.3% | -39.2% | -27.9% | |
| Q3 2021 | -5.7% | -5.1% | -5.4% | |
| Q2 2021 | +20.0% | +13.3% | +37.1% | |
| Q1 2021 | +5.1% | +2.4% | +24.8% | |
| Q4 2018 | -10.5% | -14.2% | -7.9% | |
| Q2 2020 | -3.9% | -7.8% | -1.2% | |
| Q4 2020 | -3.9% | -7.8% | -1.2% | |
| Q1 2020 | -7.3% | -29.1% | -16.5% | |
| Q3 2019 | -7.3% | -29.1% | -16.5% | |
| Q3 2020 | -7.3% | -29.1% | -16.5% | |
| Q4 2019 | -7.3% | -29.1% | -16.5% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro